All In Biotech

Drug Trial Radar · NCT00238745

Study Evaluating Bazedoxifene Dose-Response in Japanese Patients With Postmenopausal Osteoporosis.

Bone Mineral Density Increase and Safety of TSE-424 Compared to Placebo in Osteoporotic Postmenopausal Women

Last checked: Nov 20, 2026Latest source record: Dec 20, 2007 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 375 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

375

Actual

Start

Aug 2003

Primary completion

Not stated

Study completion Mar 2007

Sponsor

Sponsor type
Industry
First posted
Oct 13, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double
Who can join
Female only, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Dose-response in Japanese patients with postmenopausal osteoporosis.

Conditions

  • Postmenopausal Osteoporosis

Interventions

  • BazedoxifeneDrug

  • PlaceboDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Bone mineral density of lumbar spine (L1-L4) at 2 years.

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.